GlassScriptPhysician profile
Jude Ozuzu
NPI 1568483733
$10,425.92
in general payments reported to CMS, 2019-2025
36 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 96% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $1,133 · 2021: $1,160 · 2022: $1,853 · 2023: $2,179 · 2024: $1,362 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,586 · Education: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,586.42 |
| Education | $367.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,404.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,396.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,069.47 | 2019-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $980.87 | 2019-2025 | Fasenra, Breztri, Farxiga |
| Abbott Laboratories | $709.06 | 2019-2025 | Freestyle Libre |
| Glaxosmithkline, LLC. | $614.76 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.26 | 2019-2025 | Xifaxan, Relistor |
| Abbvie INC. | $460.76 | 2021-2025 | |
| Astellas Pharma US INC | $438.75 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $396.57 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $349.98 | 2020-2022 | |
| Horizon Therapeutics Plc | $340.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $207.53 | 2019-2024 | |
| Pfizer INC. | $198.40 | 2020-2025 | |
| Idorsia Pharmaceuticals US INC | $158.54 | 2023 | Quviviq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $157.69 | 2024 | |
| Amgen INC. | $157.31 | 2019-2024 | Evenity, Prolia |
| Teva Pharmaceuticals USA, INC. | $132.62 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $112.96 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $96.49 | 2019 | |
| Shield Therapeutics INC | $84.93 | 2025 | |
| Merck Sharp & Dohme LLC | $76.21 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $73.97 | 2021 | |
| Hikma Pharmaceuticals USA | $58.79 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $31.00 | 2023-2025 | Xtampza |
| Amarin Pharma, INC. | $23.64 | 2021 | |
| Djo, LLC | $22.87 | 2019 | |
| Exact Sciences Corporation | $22.48 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $21.94 | 2025 | Auvelity |
| Azurity Pharmaceuticals, INC. | $19.72 | 2023 | Edarbi |
| Endo Pharmaceuticals INC. | $19.15 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.54 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.05 | 2021 | |
| Eisai INC. | $13.04 | 2020 | |
| Esperion Therapeutics, INC. | $12.95 | 2020 | |
| Advanced Oxygen Therapy INC. | $12.02 | 2024 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jude Ozuzu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.